Skip to main content
Top
Published in: Breast Cancer Research 4/2001

Open Access 01-08-2001 | Research article

Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil

Authors: Sergio Koifman, Rosalina Jorge Koifman

Published in: Breast Cancer Research | Issue 4/2001

Login to get access

Abstract

Background

Increased BRCA1 and BRCA2 germline mutation rates have been reported in Ashkenazi Jewish women in North America, Europe and Israel, and have been mentioned as possibly related to a higher incidence of breast and ovarian cancer among these communities. The present study was carried out with the aim of obtaining evidence on the magnitude of breast cancer as a cause of death among Ashkenazi women in Brazil.

Methods

We reviewed all death certificates archived in the Jewish Burial Societies of São Paulo (1971-1997) and Porto Alegre (1948-1997), two of the main and oldest Jewish communities in Brazil. Breast cancer observed deaths were compared with expected deaths according to breast cancer mortality in the general population.

Results

The observed ratios were approximately quite close to unity, suggesting a similar breast cancer mortality pattern among the Ashkenazi population and the general population in both cities. These results maintain similar behavior regardless of whether analyzed before or after the mid-1980s, when mammography came to be increasingly performed in Brazil. Cancer proportional mortality ratios were 1.04 (0.83-1.29) in São Paulo and 1.16 (0.84-1.57) in Porto Alegre before 1985, and 1.17 (1.00-1.44) and 1.21 (0.81-1.79), respectively, between 1985 and 1997. Some evidence of the maintenance of protective risk factors such as high parity has been observed among Ashkenazi women in São Paulo.

Conclusion

A quite similar breast cancer mortality pattern was observed between Ashkenazi Jewish women and the general population in São Paulo and Porto Alegre, Brazil. These results may suggest an environmental role on germ mutation expression reported in this ethnic group.
Literature
1.
go back to reference Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brady LC: The carrier frequency of the BRCA1 185 delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nat Genet. 1995, 11: 198-200.PubMedCrossRef Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brady LC: The carrier frequency of the BRCA1 185 delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nat Genet. 1995, 11: 198-200.PubMedCrossRef
2.
go back to reference Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med. 1996, 334: 143-149. 10.1056/NEJM199601183340302.PubMedCrossRef Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med. 1996, 334: 143-149. 10.1056/NEJM199601183340302.PubMedCrossRef
3.
go back to reference Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L, Goldgar D: Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996, 347: 1643-1645. 10.1016/S0140-6736(96)91484-1.PubMedCrossRef Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L, Goldgar D: Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996, 347: 1643-1645. 10.1016/S0140-6736(96)91484-1.PubMedCrossRef
4.
go back to reference Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lish E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997, 60: 1059-1067.PubMedPubMedCentral Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lish E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet. 1997, 60: 1059-1067.PubMedPubMedCentral
5.
go back to reference Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Human Genet. 1998, 63: 45-51. 10.1086/301903.CrossRef Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Human Genet. 1998, 63: 45-51. 10.1086/301903.CrossRef
6.
go back to reference Gotlieb WN, Friedman E, Bar-Sade RB, Kruglikova A, Hirsch-Yechezkel G, Modan B, Inbar M, Davidson B, Kopolovic J, Novikov I, Ben-Baruch G: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst. 1998, 90: 995-1000. 10.1093/jnci/90.13.995.PubMedCrossRef Gotlieb WN, Friedman E, Bar-Sade RB, Kruglikova A, Hirsch-Yechezkel G, Modan B, Inbar M, Davidson B, Kopolovic J, Novikov I, Ben-Baruch G: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst. 1998, 90: 995-1000. 10.1093/jnci/90.13.995.PubMedCrossRef
7.
go back to reference Struewing JP: BRCA1 in special populations. Breast Dis. 1998, 10: 71-75.PubMed Struewing JP: BRCA1 in special populations. Breast Dis. 1998, 10: 71-75.PubMed
8.
go back to reference Brumer A: Caracterização demográfica e sócioeconômica da população judaica no Rio Grande do Sul. In Identidade em Mudança: Pesquisa Sociológica nos Judeus do Rio Grande do Sul. Edited by Brumer A. Federação Israelita do Rio Grande do Sul: Porto Alegre, Brasil;. 1994, 61- Brumer A: Caracterização demográfica e sócioeconômica da população judaica no Rio Grande do Sul. In Identidade em Mudança: Pesquisa Sociológica nos Judeus do Rio Grande do Sul. Edited by Brumer A. Federação Israelita do Rio Grande do Sul: Porto Alegre, Brasil;. 1994, 61-
9.
go back to reference Ministério da Saúde: Estatísticas de Mortalidade, Brasil: Secretaria Nacional de Ações Básicas de Saúde,. 1980 Ministério da Saúde: Estatísticas de Mortalidade, Brasil: Secretaria Nacional de Ações Básicas de Saúde,. 1980
10.
go back to reference Ministério da Saúde: Estatísticas de Mortalidade, Brasil: Secretaria Nacional de Ações Básicas de Saúde,. 1994 Ministério da Saúde: Estatísticas de Mortalidade, Brasil: Secretaria Nacional de Ações Básicas de Saúde,. 1994
11.
go back to reference Puffer RR, Griffith GW: Caracteristicas de la Mortalidade Urbana, Scientific Publication 151. Washington, DC: Pan American Health Organization,. 1968 Puffer RR, Griffith GW: Caracteristicas de la Mortalidade Urbana, Scientific Publication 151. Washington, DC: Pan American Health Organization,. 1968
12.
go back to reference Schnitman A: Análise da fidedignidade da declaração da causa básica de morte por câncer em Salvador, Brazil. Rev Saude Publ. 1990, 24: 490-496.CrossRef Schnitman A: Análise da fidedignidade da declaração da causa básica de morte por câncer em Salvador, Brazil. Rev Saude Publ. 1990, 24: 490-496.CrossRef
13.
go back to reference Monteiro GTR, Koifman RJ, Koifman S: Reliability and accuracy of reported causes of death from cancer: I. Reliability of all cancer reported in the State of Rio de Janeiro, Brazil. Cad Saude Publ. 1997, 13(suppl 1): S39-S52.CrossRef Monteiro GTR, Koifman RJ, Koifman S: Reliability and accuracy of reported causes of death from cancer: I. Reliability of all cancer reported in the State of Rio de Janeiro, Brazil. Cad Saude Publ. 1997, 13(suppl 1): S39-S52.CrossRef
14.
go back to reference Newman B, Millikan RC, King M-C: Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 1997, 19: 69-79.PubMedCrossRef Newman B, Millikan RC, King M-C: Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 1997, 19: 69-79.PubMedCrossRef
15.
go back to reference Mittelman M, Lewinski UH, Weiss H, Cohen AM, Djaldetti M, Pick AI: Secondary myelodisplastic syndrome in multiple myeloma - a study of nine patients with an attempt to detect myeloma patients at risk. Haematologia (Budapest). 1994, 26: 67-74. Mittelman M, Lewinski UH, Weiss H, Cohen AM, Djaldetti M, Pick AI: Secondary myelodisplastic syndrome in multiple myeloma - a study of nine patients with an attempt to detect myeloma patients at risk. Haematologia (Budapest). 1994, 26: 67-74.
16.
go back to reference Zirvi M, Nakayama T, Newman G, McCaffrey T, Patty P, Barany F: Ligase-based detection of mononucleotide repeat sequences. Nucleic Acids Res. 1999, 27: e40-10.1093/nar/27.24.e40.PubMedPubMedCentralCrossRef Zirvi M, Nakayama T, Newman G, McCaffrey T, Patty P, Barany F: Ligase-based detection of mononucleotide repeat sequences. Nucleic Acids Res. 1999, 27: e40-10.1093/nar/27.24.e40.PubMedPubMedCentralCrossRef
17.
go back to reference Lu KH, Kramer DW, Muto MG, Li EY, Niloff J, Mosk SC: A population-based study of BRCA1 and BRCA2 mutation in Jewish women with epithelial ovarian cancer. Obstet Gynecol. 1999, 93: 34-37. 10.1016/S0029-7844(98)00362-7.PubMedCrossRef Lu KH, Kramer DW, Muto MG, Li EY, Niloff J, Mosk SC: A population-based study of BRCA1 and BRCA2 mutation in Jewish women with epithelial ovarian cancer. Obstet Gynecol. 1999, 93: 34-37. 10.1016/S0029-7844(98)00362-7.PubMedCrossRef
18.
go back to reference Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U: BRCA1 germline mutations in women with uterine serous papilocarcinoma. Obstet Gynecol. 2000, 96: 28-32. 10.1016/S0029-7844(00)00851-6.PubMedCrossRef Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U: BRCA1 germline mutations in women with uterine serous papilocarcinoma. Obstet Gynecol. 2000, 96: 28-32. 10.1016/S0029-7844(00)00851-6.PubMedCrossRef
19.
go back to reference Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagnet T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizzel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E: Mutational analysis of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat. 2000, 16: 491-501. 10.1002/1098-1004(200012)16:6<491::AID-HUMU6>3.3.CO;2-A.PubMedCrossRef Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagnet T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizzel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E: Mutational analysis of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat. 2000, 16: 491-501. 10.1002/1098-1004(200012)16:6<491::AID-HUMU6>3.3.CO;2-A.PubMedCrossRef
20.
go back to reference Mondini L, Monteiro CA: Changes in diet pattern of the Brazilian urban population (1962-1988). Rev Saude Publ. 1994, 28: 433-439.CrossRef Mondini L, Monteiro CA: Changes in diet pattern of the Brazilian urban population (1962-1988). Rev Saude Publ. 1994, 28: 433-439.CrossRef
22.
go back to reference Newman B, Liu ET: Perspective on BRCA1. Breast Dis. 1998, 10: 3-10.PubMed Newman B, Liu ET: Perspective on BRCA1. Breast Dis. 1998, 10: 3-10.PubMed
Metadata
Title
Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil
Authors
Sergio Koifman
Rosalina Jorge Koifman
Publication date
01-08-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr305

Other articles of this Issue 4/2001

Breast Cancer Research 4/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine